We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Science Group Plc | LSE:SAG | London | Ordinary Share | GB00B39GTJ17 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 415.00 | 410.00 | 420.00 | 415.00 | 415.00 | 415.00 | 1,076 | 07:44:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Consulting Svcs,nec | 98.82M | 10.56M | 0.2322 | 17.87 | 188.65M |
TIDMSAG
RNS Number : 5017V
Science Group PLC
24 July 2018
24 July 2018
SCIENCE GROUP PLC
("Science Group" or the "Group" or the "Company")
INTERIM RESULTS
FOR THE SIX MONTH PERIODED 30 JUNE 2018
Summary
H1-18m H1-17m ------------------------------------------- -------- -------- Group revenue GBP25.1m GBP18.0m -------- -------- Adjusted operating profit * GBP3.7m GBP3.2m -------- -------- Statutory operating profit GBP2.7m GBP2.5m -------- -------- Statutory profit before tax GBP2.5m GBP2.3m -------- -------- Adjusted basic earnings per share * 7.0p 6.1p -------- -------- Statutory basic earnings per share 6.0p 5.1p -------- -------- Net funds * GBP5.1m GBP12.1m -------- -------- Net-funds-plus-freehold-property-per-share * 66.8p 86.2p -------- --------
Enquiries:
Science Group plc Martyn Ratcliffe, Chairman Tel: +44 (0) 1223 875 200 Rebecca Archer, Finance Director www.sciencegroup.com Panmure Gordon (UK) Limited Dominic Morley / Alina Vaskina (Corporate Tel: +44 (0) 20 7886 Finance) 2500 Erik Anderson (Corporate Broking)
* Alternative performance measures are provided in order to enhance the shareholders' ability to evaluate and analyse the underlying financial performance of the Group. Refer to Note 1 for detail and explanation of the measures used.
Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulations.
Interim Results 2018
Science Group plc (the 'Company') together with its subsidiaries ('Science Group' or the 'Group') is an international consultancy providing applied science, product development, technology advisory and regulatory services to a client base in medical, commercial and food & beverage markets.
The first half of 2018 has seen continued solid financial performance and good progress on the integration of Technology Sciences Group ('TSG'), acquired in September 2017. Benefitting from the acquisition, the Group reports record revenues, converting into strong adjusted operating profit growth and an adjusted earnings per share increase of 15%. The balance sheet of the Group remains very strong with significant cash resources and freehold property assets.
Group Financial Performance
For the six months ended 30 June 2018, the Group generated adjusted operating profit of GBP3.7 million (H1 2017: GBP3.2 million) in line with the Board's expectations, on revenue of GBP25.1 million (H1 2017: GBP18.0 million). Adjusted earnings per share increased to 7.0 pence (H1 2017: 6.1 pence).
Profit before tax was GBP2.5 million (H1 2017: GBP2.3 million). Profit after tax of GBP2.4 million (H1 2017: GBP2.0 million) includes a corporation tax charge of GBP0.1 million (H1 2017: GBP0.3 million) which benefitted from a tax credit of GBP0.2m relating to share options exercised in the period. Basic earnings per share was 6.0 pence (H1 2017: 5.1 pence) and diluted earnings per share in H1 2018 was 5.8 pence (H1 2017: 5.0 pence). At 30 June 2018, the Company had 40.0 million shares in issue (excluding treasury shares) compared to 39.4 million at 30 June 2017.
Approximately 85% (H1 2017: 80%) of the Group's Core Business revenue is derived from international markets, with 32% being denominated in US Dollars (H1 2017: 32%) and 26% in Euros (H1 2017: 9%). The remaining international clients, primarily in Europe, are invoiced in Sterling. The average US Dollar exchange rate in the period was 1.38 (H1 2017: 1.26 and H2 2017: 1.32) and the average Euro exchange rate in the period was 1.14 (H1 2017: 1.17 and H2 2017: 1.12). As a result, the net effect of currency movements during the period on Core Business revenue and adjusted operating profit, relative to the prior year on a like for like basis, was a negative GBP0.3 million.
The Group retains a robust balance sheet with Gross Cash at 30 June 2018 of GBP18.5 million (30 June 2017: GBP26.3 million) and Net Funds of GBP5.1 million (30 June 2017: GBP12.1 million). In aggregate, Net Funds plus Freehold Property total GBP26.7 million (30 June 2017: GBP33.9 million) equivalent to 66.8 pence per share (30 June 2017: 86.2 pence per share), based on the balance sheet (cost-based) value of the freehold property, which is at the bottom end of the range of independent market valuations (as at March 2018).
Business Sector Review
The Applied Science and Product Development activities, accounting for 48% of Core Business revenue, reported growth on both a year-on-year and sequential period basis. The Medical sector delivered a strong performance in the period while the Commercial sector declined compared to the prior year, due to completion of some larger projects, sustaining revenue in line with the second half of 2017.
Following the acquisition of TSG, the Group's Regulatory Services now account for 37% of Core Business revenue. Taking into account the acquisition integration impact, both TSG America and TSG Europe delivered performance in line with expectations, while the Leatherhead Food & Beverage Regulatory Services continued to make good progress.
The Technology Advisory Services, accounting for 14% of Core Business revenue, reported a flat performance. The sector structure within Technology Advisory increasingly aligns with other parts of the Group. Similar to the Applied Science and Product Development business models, the Advisory model mitigates volatility within any vertical market through a talented, scalable team of international scientific consultants who can operate across a diversity of industries.
Strategic and Corporate Developments
Following the TSG acquisition, the initial priority was to improve the financial and business processes in TSG America. This programme has also included a market segmentation initiative to improve profitability and reduce credit risk within the North American business. Good progress has been made during the first half of 2018.
In parallel, standardised policies and processes were also introduced into TSG Europe. However, during the first half of 2018, and coinciding with the appointment of a Head of the TSG European business, it became apparent that the strategy needed to be reviewed to focus on the larger European geographies which offer greater potential. As a result, in June, a new subsidiary in France was launched and a team recruited to service this strategic market where TSG had previously had minimal presence. In contrast, it became apparent that the small operations across Central/Eastern Europe, with an average of 2 consultants in each country, were absorbing a disproportionate amount of management and support resource relative to their profit contribution and future market potential. As a result, it was decided to close these sub-scale subsidiaries/branches and to appoint associate organisations, as deployed in other territories, to support multi-national clients in a more efficient business model.
With regard to the wider Science Group, where each business unit provides science-based services into client market sectors, the operating brands align with either a service (e.g. Sagentia with product development) or a market (e.g. Leatherhead Food Research with the food & beverage industry). Over time, the boundaries of these business units are increasingly blurred which enables the wider marketing of the Group's breadth of services to our clients. To that end, the Group adopts a flexible resource model with alignment of incentive programmes to encourage collaboration and mobility between businesses. This approach also enables investment in areas of higher potential. During the first half of 2018, this evolutionary process continued, particularly within the Food & Beverage market and the Group organisation will continue to evolve along this path over the next 6-12 months.
The Board is also exploring the merits of separating the Harston Mill building from the Sagentia operations. This is a legacy structure which was tax efficient but now limits the benefits that could be derived from the Group's freehold asset base and the separation of trading and property activities. However, any change in the ownership of Harston Mill, even within the Group, would result in a tax cash outflow in the range of GBP1.8 million to GBP2.1 million. The Group already carries a liability of GBP1.7 million on the balance sheet and it may be feasible to offset a proportion of the tax impact over a period of time through use of tax losses in the company previously used for the Group's legacy investments.
Summary
In summary, the Group financial performance in the first half of 2018 has been in line with the Board's expectations. The Group's balance sheet remains very strong including significant cash resources. The long term debt is secured against the Group's freehold property.
The integration of TSG is progressing satisfactorily, with improvements in financial controls and operating processes already translating into improved profitability. The strategy evolution of the North American business has been based around market segmentation while the European strategy developments have refocused the business on the major European markets whilst maintaining the wide geographical coverage to service TSG clients.
The Group strategy is continually evolving which is essential in a leading science & technology business. The combination of outstanding science, engineering, regulatory and advisory resources, providing leading edge technology services into vertical market sectors led by managers with deep industry knowledge and experience, provides a differentiated business model. Combining that outstanding capability with disciplined financial and commercial management, is the enabler for delivering shareholder value.
Consolidated Income Statement
For the period ended 30 June 2018
Six months Six months Year ended ended ended 30 June 30 June 31 December 2018 2017 2017 (Unaudited) (Unaudited) (Audited) Notes GBP000 GBP000 GBP000 ------------ ------------- ------------ Revenue 4 25,135 18,020 40,823 Operating expenses before adjusting items (21,427) (14,783) (33,917) Adjusted operating profit 4 3,708 3,237 6,906 ------------ ------------- ------------ Amortisation and impairment of intangible assets (1,003) (557) (1,410) Acquisition integration costs (282) - (812) Release of contingent consideration 8 519 - - Share based payment charge (232) (132) (312) Operating profit 4 2,710 2,548 4,372 Finance income 1 - 3 Finance costs (221) (245) (496) Profit before income tax 2,490 2,303 3,879 Income tax charge (including R&D tax credit of GBP154,000 (H1-17 GBP155,000)) 6 (116) (306) (861) ------------ ------------- ------------ Profit for the period 4 2,374 1,997 3,018 ------------ ------------- ------------ Profit for the period attributable to equity holders of the parent 2,374 1,997 3,018 Earnings per share Earnings per share from continuing operations (basic) 7 6.0p 5.1p 7.7p Earnings per share from continuing operations (diluted) 7 5.8p 5.0p 7.5p Adjusted earnings per share from continuing operations (basic) 7 7.0p 6.1p 12.8p Adjusted earnings per share from continuing operations (diluted) 7 6.8p 6.0p 12.5p ------------ ------------- ------------
Consolidated Statement of Comprehensive Income
For the period ended 30 June 2018
Six months Six months Year ended ended ended 30 June 30 June 31 December 2018 2017 2017 (Unaudited) (Unaudited) (Audited) GBP000 GBP000 GBP000 ------------ ------------ ------------ Profit for the period 2,374 1,997 3,018 Other comprehensive income Items that will or may be reclassified to profit or loss: Fair value gain on interest rate swap, net of tax 132 70 30 Exchange differences on translating foreign operations (30) 3 (28) Deferred tax on interest rate swap (25) - (5) Deferred tax on interest rate swap - prior period adjustment - - (38) Other comprehensive(expense)/ income for the period 77 73 (41) ------------ ------------ ------------ Total comprehensive income for the period 2,451 2,070 2,977 ------------ ------------ ------------ Total comprehensive income for the period attributable to owners of the parent 2,451 2,070 2,977 ------------ ------------ ------------
Consolidated Statement of Changes in Shareholders' Equity
For the period ended 30 June 2018
Group Issued Share Treasury Merger Translation Share based Retained Total capital premium Stock reserve reserve payment earnings - reserve Shareholders GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 funds GBP000 ---------------------- -------- -------- -------- -------- ----------- ----------- --------- Balance at 1 January 2017 421 8,230 (3,608) 10,343 338 2,351 17,928 36,003 Issue of shares out of treasury stock - - 34 - - - (20) 14 Dividends - - - - - - (1,653) (1,653) Share based payment charge - - - - - 132 - 132 Deferred tax on share based payment transactions - - - - - - 145 145 ---------------------- -------- -------- -------- -------- ----------- ----------- --------- ------------- Transactions with owners - - 34 - - 132 (1,528) (1,362) ---------------------- -------- -------- -------- -------- ----------- ----------- --------- Profit for the period - - - - - - 1,997 1,997 Other comprehensive income: Fair value gain on interest rate swap - - - - - - 70 70 Exchange differences on translating foreign operations - - - - 3 - - 3 -------- -------- -------- -------- ----------- ----------- --------- ------------- Total comprehensive income for the period - - - - 3 - 2,067 2,070 ---------------------- -------- -------- -------- -------- ----------- ----------- --------- ------------- Balance at 30 June 2017 421 8,230 (3,574) 10,343 341 2,483 18,467 36,711 ---------------------- -------- -------- -------- -------- ----------- ----------- --------- Balance at 1 July 2017 421 8,230 (3,574) 10,343 341 2,483 18,467 36,711 Purchase of own - - - - - - - - shares Issue of shares out of treasury stock - - 5 - - - (4) 1 Share based payment charge - - - - - 180 - 180 Deferred tax on share based payment transactions - - - - - - (60) (60) ------------------------ --- ----- ------- ------ ---- ----- ------ ------ Transactions with owners - - 5 - - 180 (64) 121 ------------------------ --- ----- ------- ------ ---- ----- ------ Profit for the period - - - - - - 1,021 1,021 Other comprehensive income: Fair value gain on interest rate swap - - - - - - (40) (40) Exchange differences on translating foreign operations - - - - (31) - - (31) Deferred tax on interest rate swap - - - - - - (43) (43) Total comprehensive income for the period - - - - (31) - 938 907 ------------------------ --- ----- ------- ------ ---- ----- ------ Balance at 31 December 2017 421 8,230 (3,569) 10,343 310 2,663 19,341 37,739
------------------------ --- ----- ------- ------ ---- ----- ------ Balance at 1 January 2018 421 8,230 (3,569) 10,343 310 2,663 19,341 37,739 Purchase of own shares - - (180) - - - - (180) Issue of shares out of treasury stock - - 954 - - - (840) 114 Dividends paid - - - - - - (1,760) (1,760) Share based payment charge - - - - - 232 - 232 Deferred tax on share based payment transactions - - - - - - (112) (112) ---------------------- --- ----- ------- ------ ---- ----- ------- ------- Transactions with owners - - 774 - - 232 (2,712) (1,706) ---------------------- --- ----- ------- ------ ---- ----- ------- Profit for the period - - - - - - 2,374 2,374 Other comprehensive income: Fair value gain on interest rate swap - - - - - - 132 132 Exchange differences on translating foreign operations - - - - (30) - - (30) Deferred tax on interest rate swap - - - - - - (25) (25) ---------------------- --- ----- ------- ------ ---- ----- ------- ------- Total comprehensive income for the period - - - - (30) - 2,481 2,451 ---------------------- --- ----- ------- ------ ---- ----- ------- ------- Balance at 30 June 2018 421 8,230 (2,795) 10,343 280 2,895 19,110 38,484 ---------------------- --- ----- ------- ------ ---- ----- -------
Consolidated Balance Sheet
At 30 June 2018
At 31 At 30 June At 30 June December 2018 2017 2017 (Unaudited) (Unaudited) (Audited) GBP000 GBP000 GBP000 (Restated) ------------- ------------- ----------- Assets Non-current assets Acquisition related intangible assets 8,496 4,626 9,499 Goodwill 11,535 4,033 11,535 Property, plant and equipment 23,438 23,556 23,787 Investments 50 50 50 Derivative financial assets 359 267 227 Deferred tax assets 160 333 104 44,038 32,865 45,202 ------------- ------------- ----------- Current assets Trade and other receivables 8,912 5,716 9,381 Current tax asset 20 21 - Cash and cash equivalents - Client registration funds 1,241 - 887 Cash and cash equivalents - Group Cash 18,522 26,284 19,893 ------------- ------------- ----------- 28,695 32,021 30,161 ------------- ------------- ----------- Total assets 72,733 64,886 75,363 ------------- ------------- ----------- Liabilities Current liabilities Trade and other payables 15,798 11,859 18,208 Current tax liabilities 521 - 554 Provisions 1,136 - 825 Borrowings 1,250 1,000 1,250 ------------- ------------- ----------- 18,705 12,859 20,837 ------------- ------------- ----------- Non-current liabilities Provisions 339 - 466 Borrowings 12,182 13,169 12,676 Contingent consideration - - 519 Deferred tax liabilities 3,023 2,147 3,126 ------------- ------------- ----------- 15,544 15,316 16,787 ------------- ------------- ----------- Total liabilities 34,249 28,175 37,624 ------------- ------------- ----------- Net assets 38,484 36,711 37,739 ------------- ------------- ----------- Shareholders' equity Share capital 421 421 421 Share premium 8,230 8,230 8,230 Treasury stock (2,795) (3,574) (3,569) Merger reserve 10,343 10,343 10,343 Translation reserves 280 341 310 Share based payment reserve 2,895 2,483 2,663 Retained earnings 19,110 18,467 19,341 ------------- ------------- ----------- Total equity 38,484 36,711 37,739 ------------- ------------- -----------
Restatement: It was identified that at 31 Dec 2017, a balance of GBP1.2m was incorrectly disclosed gross within Amounts recoverable on contracts and Payments received on account (disclosed within Trade and other receivables and Trade and other payables respectively) whereas there was a right of offset and hence should have been disclosed on a net basis. An adjustment as at 31 Dec 2017 has been recognised to reduce both these balances by GBP1.2m. This adjustment has not affected net assets.
Consolidated Statement of Cash Flows
For the period ended 30 June 2018
Six months Six months Year ended ended ended 31 December 30 June 30 June 2017 2018 2017 (Audited) (Unaudited) (Unaudited) GBP000 GBP000 GBP000 ------------ ------------- ------------ Operating profit 2,710 2,548 4,372 Adjustments for: Amortisation on acquisition related intangible assets 1,003 557 1,410 Depreciation on property, plant and equipment 396 358 728 Release of contingent consideration (519) - - Movement in provisions 334 - - Settlement of onerous lease provision (150) - - Share based payment charge 232 132 312 Decrease in receivables 225 2,508 1,406 Increase in payables representing client registration funds 354 - 887 Decrease in payables excluding balances representing client registration funds (2,526) (3,329) (469) ------------ ------------- ------------ Cash generated from operations 2,059 2,774 8,646 Finance costs (221) (245) (386) UK corporation tax (paid) / received (466) 41 (91) Foreign corporation tax received - - 19 ------------ ------------- ------------ Cash flows from operating activities 1,372 2,570 8,188 ------------ ------------- ------------ Interest received 1 - 3 Purchase of property, plant and equipment (43) (121) (471) Purchase of subsidiary undertakings, net of cash received - - (10,435) Cash flow used in investing activities (42) (121) (10,903) Issue of shares out of treasury 114 14 15 Repurchase of own shares (180) - - Dividends paid (1,760) (1,653) (1,653) Repayment of bank loans (500) (500) (750) Cash flows used in financing
activities (2,326) (2,139) (2,388) ------------ ------------- ------------ Increase in cash and cash equivalents in the period (996) 310 (5,103) Cash and cash equivalents at the beginning of the period 20,780 25,996 25,996 Exchange (losses) / gains on cash (21) (22) (113) Cash and cash equivalents at the end of the period 19,763 26,284 20,780 ------------ ------------- ------------
Cash and cash equivalents is analysed as follows:
Six months Six months Year ended ended ended 31 December 30 June 30 June 2017 2018 2017 (Audited) (Unaudited) (Unaudited) GBP000 GBP000 GBP000 ----------------------------------- ------------ ------------ ------------ Cash and cash equivalents - Client registration funds 1,241 - 887 Cash and cash equivalents - Group cash 18,522 26,284 19,893 ----------------------------------- ------------ ------------ ------------ 19,763 26,284 20,780 ----------------------------------- ------------ ------------ ------------
Extracts from notes to the financial statements
1. General information
The financial information for the 6 months ended 30 June 2018 set out in this interim report is unaudited and does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The financial information included has been extracted from the 2017 Financial Statements of Science Group plc. The Group's statutory financial statements for the year ended 31 December 2017 have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain a statement under Section 498(2) or Section 498(3) of the Companies Act 2006.
These un-audited interim results have been approved for issue by the Board of Directors on 23 July 2018.
The group and company financial statements of Science Group plc for the year ended 31 December 2017 were prepared under IFRS (as adopted by the EU) and have been audited by KPMG LLP. Copies of the Financial Statements are available from the company's registered office: Harston Mill, Harston, Cambridge, CB22 7GG and can be found on the company's website at www.sciencegroup.com.
Science Group plc (the 'Company') and its subsidiaries (together 'Science Group' or 'Group') is an international consultancy providing applied science, product development, technology advisory and regulatory services to a client base in medical, food & beverage and commercial markets.
The Company is the ultimate parent company in which results of all the Science Group companies are consolidated.
The Company is incorporated in England and Wales and has its primary listing on the AIM Market of the London Stock Exchange (SAG).
Alternative performance measures
The Group uses alternative (non-Generally Accepted Accounting Practice ('non-GAAP')) performance measures of 'adjusted operating profit', 'adjusted earnings per share', 'net funds' and 'net-funds-plus-freehold-property-per-share in issue' which are not defined within the International Financial Reporting Standards ('IFRS'). These are explained in the 2017 Financial Statements and the calculations are as follows:
(a) Adjusted operating profit
The calculation of this measure is shown on the Consolidated Income Statement.
(b) Adjusted earnings per share
The calculation of this measure is disclosed in Note 7.
(c) Net funds
This measure is calculated as follows:
In GBP000 unless otherwise At 31 December stated At 30 June At 30 June 2017 2018 2017 --------------------------- ------------ ------------ -------------- Cash and cash equivalents - Group cash 18,522 26,284 19,893 Borrowings (13,432) (14,169) (13,926) --------------------------- ------------ ------------ -------------- Net funds 5,090 12,115 5,967 --------------------------- ------------ ------------ --------------
(d) Net-funds-plus-freehold-property-per-share in issue
The Group calculates this measure as follows:
In GBP000 unless otherwise At 31 December stated At 30 June At 30 June 2017 2018 2017 ------------------------------------------- ------------ ------------ -------------- Net funds 5,090 12,115 5,967 Freehold land and buildings 21,639 21,799 21,719 ------------------------------------------- ------------ ------------ -------------- Net funds plus freehold property 26,729 33,914 27,686 Number of shares in issue (excluding treasury shares) ('000 shares) 40,015 39,363 39,367 ------------------------------------------- ------------ ------------ -------------- Net-funds-plus-freehold-property-per-share in issue (pence) 66.8 86.2 70.3 ------------------------------------------- ------------ ------------ --------------
2. Accounting policies
The principal accounting policies applied in the preparation of these interim financial statements are unchanged from those set out in the financial statements for the year ended 31 December 2017 except as described below in Note 2.2. These policies have been consistently applied to all the periods presented except where detailed below.
2.1 Basis of preparation
These interim consolidated financial statements are for the six months ended 30 June 2018. They have been prepared based on the measurement and recognition principles of International Financial Reporting Standards as adopted by the EU and IFRC interpretations issued and effective at the time of preparing these statements.
The financial statements have been prepared on the historical cost basis except for certain financial instruments and share based payments which are measured at fair value.
2.2 Changes in accounting policies
This is the first set of the Group's financial statements where IFRS 15 and IFRS 9 have been applied. The Group has adopted IFRS 15 Revenue from Contracts with Customers and IFRS 9 Financial Instruments from 1 January 2018. A number of other new standards are effective from 1 January 2018 but they do not have a material effect on the Group's financial statements.
Impact on transition
The effect of initially applying these two standards with regards to recognition and measurement is an immaterial impact on the results of the Group and hence no restatement has been made. The basis of this conclusion for each of the accounting standard changes is as follows:
IFRS 15 Revenue from Contracts with Customers
The key principle that was considered on transition of this accounting standard was whether revenue is recognised at a point in time or over a period of time as the services are performed. It was concluded that revenue is recognised under IFRS 15 as the time is worked at the fee rate specified within the contract; the majority of projects are performed on a time and materials basis under which i) all work performed is fully transferable to the client at any point during the project and ii) the Company has the right to receive payment for its services performed up to any given point in time.
IFRS 9 Financial Instruments
At the reporting date, the only complex financial instruments that the Group holds are interest rate swaps for which hedge accounting applies. There is no effect on these financial instruments on the transition to the new accounting standard with it continuing to be measured at Fair Value Through Comprehensive Income and hence no restatement is required.
The application of the IFRS 9 'expected credit loss' model does not have a material impact on the level of impairment of receivables.
The updated accounting policies have been provided below and the disclosures have been provided in line with the requirements of IFRS 15 Revenue from Contracts with Customers and IAS 34 Interim Financial Reporting.
The group has applied IFRS 15 and IFRS 9 from 1 January 2018 and has elected to not restate comparative information. The Group has adopted the cumulative effect method at the point of initial application of these standards (i.e. 1 January 2018) and there is no material impact on brought forward retained earnings. As a result, the comparative information provided continues to be accounted for in accordance with the group's previous accounting policy as disclosed in the financial statements for the year ended 31 December 2017.
The accounting policies that reflect the new accounting standards for IFRS 15 and IFRS 9 are effective from 1 January 2018 and are as follows:
Revenue recognition
The Core Business segment provides consultancy services to clients across the medical, commercial and food & beverage markets. Revenue from providing services is recognised in the accounting period in which the services are rendered. The majority of projects are priced on a time and materials basis and the revenue for these projects is recognised based on the actual labour hours spent at the contractual fee rates.
For the few fixed-price project contracts, revenue is recognised based on the proportion of deliverables provided to the client with an adjustment if the project is forecast to overrun.
Subscription income for membership services provided over an annual contractual period is recognised in the income statement on a straight-line basis over the period of the contract.
The Non-Core Business segment includes all revenue generated from a property owned by the Group and this is recognised in the related period on a straight-line basis over the lease term. All lease contractual notice periods are shorter than 12 months.
Revenue is measured and recognised using the contractual fee rates of the project. Estimates of revenues or extent of progress toward completion are revised if circumstances change. Any resulting increases or decreases in estimated revenues are reflected in profit or loss in the period in which the circumstances that give rise to the revision become known by management.
In the case of both time and material and fixed-price contracts, the customer pays for the value of services provided based on an invoicing and payment schedule. If the services rendered by the Group at the reporting date exceed the payments received to date, a contract asset is recognised (within trade receivables if the sales invoice has been raised or amounts recoverable on contracts if the services rendered have not been invoiced). If the payments exceed the services rendered, a contract liability is recognised.
In the majority of cases, customers are invoiced on a monthly basis however this varies when appropriate to take into account credit limits, payment terms and operational efficiencies. Consideration is payable when invoiced based on contractual payment terms.
Financial instruments
(a) Classification
From 1 January 2018, the Group classifies its financial assets in the following measurement categories:
(i) those to be measured subsequently at fair value (either through other comprehensive income, or through profit or loss), and
(ii) those to be measured at amortised cost.
The classification depends on the Group's business model for managing the financial assets and the contractual terms of the cash flows.
For assets measured at fair value, gains and losses will either be recorded in profit or loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income.
(b) Measurement
At initial recognition, the group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed in profit or loss.
Debt instruments
Subsequent measurement of debt instruments depends on the group's business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the group classifies its debt instruments:
(i) Amortised cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. A gain or loss on a debt investment that is subsequently measured at amortised cost and is not part of a hedging relationship is recognised in profit or loss when the asset is derecognised or impaired.
(ii) Fair value through other comprehensive income (FVOCI): Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses and interest revenue which are recognised in profit or loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to profit or loss and recognised in other gains/(losses). Interest income from these financial assets is included in finance income using the effective interest rate method.
(iii) Fair value through profit or loss: Assets that do not meet the criteria for amortised cost or FVOCI are measured at fair value through profit or loss. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss and is not part of a hedging relationship is recognised in profit or loss and presented net in the statement of profit or loss within other gains/(losses) in the period in which it arises.
Equity instruments
The group subsequently measures all equity investments at fair value. Where the group's management has elected to present fair value gains and losses on equity investments in other comprehensive income, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognised in profit or loss as other income when the group's right to receive payments is established.
Changes in the fair value of financial assets at fair value through profit or loss are recognised in other gain/(losses) in the statement of profit or loss as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value
(c) Impairment
The group assesses on a forward looking basis the expected credit losses associated with its debt instruments carried at amortised cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk. For trade receivables, the group applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables.
2.3 Standards issued not yet effective
The Group has the following update to information provided in the last annual financial statements about the standards issued but not yet effective that may have a significant impact on the Group's consolidated financial statements.
IFRS 16 Leases
IFRS 16 replaces existing leases guidance, including IAS 17 Leases, and the standard is effective for annual periods beginning on or after 1 January 2019.
IFRS 16 introduces a single, on-balance sheet lease accounting model for lessees. A lessee recognises a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments.
The Group has completed an initial assessment of the potential impact on its consolidated financial statements but has not yet completed its detailed assessment. The actual impact of applying IFRS 16 will depend on future economic conditions, including the composition of the Group's lease portfolio at that date, the Group's latest assessment of whether it will exercise any lease renewal options and the extent to which the Group chooses to use practical expedients and recognition exemptions.
Thus far, the most significant impact identified is that the Group will recognise new assets and liabilities for its operating leases of offices spaces. As at 30 June 2018, only some of the Group's property leases meet the criteria to be accounted for under IFRS 16 due to the contractual terms and materiality of the tenancies. For these leases, the Group's future minimum lease payments under non-cancellable operating leases amounted to GBP2.8 million on an undiscounted basis.
In addition, the nature of expenses related to those leases will now change because IFRS 16 replaces the straight-line operating lease expense with a depreciation charge for right-of-use assets and interest expense on lease liabilities.
3. Financial risk management
3.1 Financial risk factors
The Group's activities expose it to a variety of financial risks: market risk (including currency risk, fair value interest risk and price risk), credit risk, liquidity risk and cash flow interest-rate risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance.
4. Segmental information
Science Group is organised on a worldwide basis into two segments, Core Business and Non-Core Business. 'Core Business' services revenue includes all consultancy fees for services operations. 'Core Business' other revenue includes recharged materials and expenses and product/licence revenue generated directly from all 'Core Business' activities. 'Non-Core Business' activities include rental income from Harston Mill and income from the provision of external IT services. The segmental analysis is reviewed to operating profit. Other resources are shared across the Group.
Period ended 30 June 2018 Core Non-Core (Unaudited) Business Business Total GBP000 GBP000 GBP000 --------- --------- ------- Services revenue 23,918 2 23,920 Third party property income - 515 515 Other 700 - 700 Revenue 24,618 517 25,135 --------- --------- ------- Adjusted operating profit 3,643 65 3,708 --------- --------- ------- Amortisation and impairment of intangible assets (1,003) - (1,003) Release of contingent consideration 519 - 519 Acquisition and integration costs (282) - (282) Share based payment charge (232) - (232) Operating profit 2,645 65 2,710 --------- --------- ------- Finance charges (net) (220) --------- --------- ------- Profit before income tax 2,490 --------- --------- ------- Income tax charge (116) --------- --------- ------- Profit for the period 2,374 --------- --------- ------- Period ended 30 June 2017 Core Non-Core (Unaudited) Business Business Total GBP000 GBP000 GBP000 --------- --------- ------- Services revenue 16,801 18 16,819 Third party property income - 544 544 Other 657 - 657 Revenue 17,458 562 18,020 --------- --------- ------- Adjusted operating profit 3,132 105 3,237 --------- --------- ------- Amortisation and impairment of intangible assets (557) - (557) Share based payment charge (132) - (132) Operating profit 2,443 105 2,548 --------- --------- ------- Finance charges (net) (245) --------- --------- ------- Profit before income tax 2,303 --------- --------- ------- Income tax charge (306) --------- --------- ------- Profit for the period 1,997 --------- --------- ------- Year ended 31 December 2017 Core (Audited) Non-Core Business Business Total GBP000 GBP000 GBP000 --------- --------- ------- Services revenue 38,365 39 38,404 Third party property income - 1,080 1,080 Other 1,339 - 1,339 Revenue 39,704 1,119 40,823 --------- --------- ------- Adjusted operating profit 6,709 197 6,906 --------- --------- ------- Amortisation and impairment of intangible assets (1,410) - (1,410) Acquisition integration costs Acquisition integration costs (812) - (812) Share based payment charge (312) - (312) Operating profit 4,175 197 4,372 --------- --------- ------- Finance charges (net) (493) --------- --------- ------- Profit before income tax 3,879 --------- --------- ------- Income tax charge (861) --------- --------- ------- Profit for the period 3,018 --------- --------- -------
5. Revenue
The Group's operations and main revenue streams are those described in the last annual financial statements and Note 4. The Group's revenue is derived from contracts with customers.
Disaggregation of revenue
In the following table, revenue is disaggregated by geographical market and by the currency in which the contract is denominated. The table includes Core Business Revenue; all Non-Core Business Revenue is generated in the UK and denominated in GBP.
For the 6 months ended June (Unaudited) USD EUR GBP Other Total Currency GBP000 GBP000 GBP000 GBP000 GBP000 ------------- ------- ------- ------- ------- 2018 7,888 6,405 10,295 30 24,618 2017 5,559 1,625 10,274 - 17,458 Europe (excl North America UK) UK Other Total Geographical market GBP000 GBP000 GBP000 GBP000 GBP000 ------------- ------- ------- ------- ------- 2018 8,989 10,462 3,671 1,496 24,618 2017 7,316 6,033 3,511 598 17,458 ------------- ------- ------- ------- -------
6. Income tax
The income tax charge for the period ended 30 June 2018 is charged at the effective tax rate calculated for the period using reasonable estimates and incorporating both current and deferred taxation:
Six months Six months Year ended ended ended 31 December 30 June 2018 30 June 2017 2017 (Unaudited) (Unaudited) (Audited) GBP000 GBP000 GBP000 ------------- ------------- ------------ Profit before tax 2,490 2,303 3,879 ------------- ------------- ------------ Current taxation (590) (630) (1,281) Current taxation - adjustment in respect of prior years 24 - (34) Deferred taxation 296 169 196 Deferred taxation - adjustment in respect of prior years - - (50) R&D tax credit 154 155 308 ------------- ------------- ------------ Tax charge (116) (306) (861) ------------- ------------- ------------ Effective tax rate 4.7% 13.3% 22.2% ------------- ------------- ------------
The Group claims Research and Development tax credits under both the R&D Expenditure Credit scheme and the Small or Medium-sized scheme. The R&D tax credit of GBP154,000 (H1 2017: GBP155,000) was recognised on an accruals basis for the period to which the R&D tax credit relates and based on a reasonable estimate of the amounts involved.
7. Earnings per share
The calculation of earnings per share is based on the following results and number of shares:
Six months Six months Year ended ended ended 31 December 2017 30 June 2018 30 June 2017 (Audited) (Unaudited) (Unaudited) GBP000 GBP000 GBP000 ------------- ------------- ------------ Profit for the financial period 2,374 1,997 3,018 ------------- ------------- ------------ Weighted average number of Number shares: For basic earnings per share 39,750,141 39,344,121 39,316,141 For fully diluted earnings per share 40,793,940 40,327,332 40,273,725 ------------- ------------- ------------ Earnings per share: Pence Pence Pence Basic earnings per share 6.0 5.1 7.7 Fully diluted earnings per share 5.8 5.0 7.5 ------------- ------------- ------------
The calculation of adjusted earnings per share is as follows:
Six months Six months Year ended ended ended 31 December 30 June 2018 30 June 2017 2017 (Unaudited) (Unaudited) (Audited) GBP000 GBP000 GBP000 ------------- ------------- ------------ Adjusted* profit after tax for the period 2,790 2,415 5,032 ------------- ------------- ------------ Weighted average number of Number Number Number shares: For basic earnings per share 39,750,141 39,344,121 39,316,141 For fully diluted earnings per share 40,793,940 40,327,332 40,273,725 ------------- ------------- ------------ Adjusted earnings per share: Pence Pence Pence Basic earnings per share 7.0 6.1 12.8 Fully diluted earnings per share 6.8 6.0 12.5 ------------- ------------- ------------
*Calculation of adjusted profit after tax:
Six months Six months Year ended ended ended 31 December 30 June 2018 30 June 2017 2017 (Unaudited) (Unaudited) (Audited) GBP000 GBP000 GBP000 ----------------------------- ------------- ------------- ------------ Adjusted operating profit 3,708 3,237 6,906 Finance income 1 - 3 Finance costs (221) (245) (496) ----------------------------- ------------- ------------- ------------ Adjusted profit before tax 3,488 2,992 6,413 Tax charge at approx blended average tax rate of 20.0% (H1-17: 19.3%) (698) (577) (1,381) ----------------------------- ------------- ------------- ------------ Adjusted profit after tax 2,790 2,415 5,032 ----------------------------- ------------- ------------- ------------
8. Contingent consideration
A contingent consideration of GBP0.5 million was recognised on acquisition of TSG in September 2017. During the 6 months ended 30 June 2018, the certain agreed conditions on the vendor ceased to be met and the contingent consideration was no longer payable. The contingent consideration was released to the Consolidated Income Statement during the period and is separately disclosed as an adjusting item.
9. Provisions
Onerous Dilapid- Restruct-uring Other Total lease ations GBP000 GBP000 GBP000 GBP000 GBP000 -------------------------------- ------- -------- -------------- ------- ------- At 1 January 2017 and - - - - - 1 July 2017 Provisions held by acquired companies at date of acquisition 495 183 - 615 1,293 Increase in provision - 16 - - 16 Gain on foreign currency fluctuations - - - (18) (18) -------------------------------- ------- -------- -------------- ------- ------- At 31 December 2017 495 199 - 597 1,291 Increase in provision - 157 199 379 735 Utilisation of provision (150) - - - (150) Release of provision not required due to settlement of contract (95) (34) - (281) (410) Loss/(Gain) on foreign currency fluctuations 6 (3) - 6 9 -------------------------------- ------- -------- -------------- ------- ------- At 30 June 2018 256 319 199 701 1,475 -------------------------------- ------- -------- -------------- ------- ------- At 30 June At 30 June At 31 December 2018 2017 2017 (Unaudited) (Unaudited) (Audited) GBP000 GBP000 GBP000 ------------------------ ------------ ------------ -------------- Current liabilities 1,136 - 825 Non-current liabilities 339 - 466 ------------------------ ------------ ------------ -------------- 1,475 - 1,291 ------------------------ ------------ ------------ --------------
The restructuring provision relates to the costs associated with the closure of the Central/Eastern Europe offices and is anticipated to be utilised during the next two years.
Other provisions represents the best estimate of the future economic outflow of settling potential litigation claims and associated costs such as legal fees. In all cases, the claims are being investigated by our lawyers and are being robustly contested as to both liability and quantum. These claims are expected to be resolved within one year of the reporting date and are therefore shown within current liabilities however, it is possible that these claims may take longer to resolve. The claim may be settled at amounts higher or lower than that provided depending on the outcome of commercial or legal arguments.
The provision recognised at the date of acquisition of TSG has been re-measured based on new information obtained about facts and circumstances subsequent to the acquisition date that existed as of the acquisition date. The provision made is management's best estimate of the Group's liability based on past experience, commercial judgement and legal advice. The re-measurement has not resulted in a material change to the total provision and hence there has been no restatement of the acquisition accounting however a reallocation of goodwill has been performed with the goodwill allocated to TSG Europe increasing by GBP210,000 and the goodwill allocated to TSG America decreasing by the same amount. This reallocation is the provision change net of deferred tax.
10. Share based remuneration schemes
During the 6 months ended 30 June 2018, 733,000 share options were exercised by employees. 1,750,000 share options were issued and 160,000 share options lapsed resulting in 2,734,000 (2017: 1,877,000) unexercised share options at the period end. Of these, 54,000 (2017: 793,000) have vested. At 30 June 2018, unexercised options granted to subscribe for ordinary shares of the company are as follows:
Option exercise Number of shares under period option =========== ================== =============================================== =========== ========= ======== ======== From To Approved Unapproved Performance Enhanced Exercise Fair Life Volatility share plan Executive Price Value (years) Incentive (pence) of Date Addendum options of grant (pence) =========== ====== ========== ================ =========== ================ =========== ========= ======== ======== =========== Nov Nov 2012 2015 Nov 2022 20,058 4,942 - - 86.0 18.6 10 40% Sep
Sep 2013 2016 Sep 2023 - - 6,666 - 1.0 80.8 10 25% Sep Sep 2014 2017 Sep 2024 - - 8,333 - 1.0 74.8 10 18% Apr Apr 2015 2018 Apr 2025 - - 14,000 - 1.0 86.7 10 16% Sep Sep 2015 2018 Sep 2025 - - 270,000 - 1.0 77.0 10 16% Aug Aug 2016 2019 Aug 2026 - - 290,000 - 1.0 96.5 10 21% Sep Sep 2016 2019 Sep 2026 - - 100,000 - 1.0 81.6 10 22% Sep Sep 2017 2020 Sep 2027 - - 270,000 - 1.0 207.1 10 24% May May 2018 2021 May 2028 - - 450,000 - 1.0 224.4 10 25% May May 2018 2023 May 2028 - - - 1,200,000 1.0 121.0 10 25% Jun Jun 2018 2021 Jun 2028 - - 100,000 - 1.0 218.4 10 25% 30-Jun-18 20,058 4,942 1,508,999 1,200,000 =============================== ================ =========== ================ =========== ========= ======== ======== ===========
During the 6 months ended 30 June 2018, share options were issued under both the Performance Share Plan ('PSP') and the Enhanced Executive Incentive scheme ('EEI') which is an addendum to the PSP.
The fair values of the options granted under the PSP in 2018 were determined using the Binomial Option Pricing model that takes into account factors specific to the share incentive plan including performance conditions. In May and June 2018, 550,000 share options were granted with conditions of the company achieving earnings per share targets with a vesting period of 3 years. These performance conditions which are market conditions have been incorporated into the measurement by means of actuarial modelling.
The fair values of the options granted under the EEI in 2018 were determined using the Monte Carlo Option Valuation model that takes into account factors specific to the share incentive plan. In May 2018, 1.2 million share options were granted under the EEI with a condition of achieving share price hurdles with a vesting period of 5 years. These performance conditions which are market conditions have been incorporated into the measurement by means of actuarial modelling.
11. Critical accounting estimates and judgements
In preparing these interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates.
The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements. No new significant judgements and key sources of estimation uncertainty were required in the application of IFRS 15 and IFRS 9.
- Ends -
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IR FKNDBABKDAOB
(END) Dow Jones Newswires
July 24, 2018 02:00 ET (06:00 GMT)
1 Year Science Chart |
1 Month Science Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions